Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Naval Refractive Surgery Center proposes a prospective, single-site, randomized, non-FDA
regulated clinical trial with bilateral commercial treatment for for PRK. Subjects will be
randomized to receive one of two postoperative steroid regimens: Dextenza (a dexamethasone
ophthalmic insert) or standard of care topical Fluorometholone. Subjects will be followed for
3 months after surgery. Investigators will use objective and subjective measures to assess
potential differences in postoperative healing and pain.
This study will not be FDA-regulated. All study surgeries will be standard of care, with the
exception of the addition of the Dextenza insert after the PRK procedure among subjects
randomized to the Dextenza group.